Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
431.24 USD | +3.69% | +2.64% | +6.73% |
Jan. 06 | UBS Adjusts Price Target on CACI International to $513 From $557, Maintains Buy Rating | MT |
Jan. 02 | CACI International Shares Rise After Upgrade From Raymond James | MT |
Fiscal Period: June | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.42 | 5.76 | 4.85 | 5.36 | 6.06 | |||||
Return on Total Capital | 6.75 | 7.22 | 6.19 | 6.78 | 7.57 | |||||
Return On Equity % | 12.78 | 17.18 | 12.83 | 12.26 | 12.46 | |||||
Return on Common Equity | 12.78 | 17.18 | 12.83 | 12.26 | 12.46 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 34.98 | 34.97 | 34.69 | 34.31 | 32.8 | |||||
SG&A Margin | 24.99 | 23.97 | 24.52 | 23.73 | 22.46 | |||||
EBITDA Margin % | 9.99 | 11 | 10.17 | 10.58 | 10.34 | |||||
EBITA Margin % | 9.09 | 10.04 | 9.2 | 9.59 | 9.45 | |||||
EBIT Margin % | 8.05 | 8.93 | 8 | 8.47 | 8.48 | |||||
Income From Continuing Operations Margin % | 5.62 | 7.57 | 5.91 | 5.74 | 5.48 | |||||
Net Income Margin % | 5.62 | 7.57 | 5.91 | 5.74 | 5.48 | |||||
Net Avail. For Common Margin % | 5.62 | 7.57 | 5.91 | 5.74 | 5.48 | |||||
Normalized Net Income Margin | 4.42 | 5.17 | 4.58 | 4.51 | 4.44 | |||||
Levered Free Cash Flow Margin | 5.48 | 4.21 | 10.98 | 5.89 | 5.13 | |||||
Unlevered Free Cash Flow Margin | 6.06 | 4.59 | 11.36 | 6.64 | 5.95 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.08 | 1.03 | 0.97 | 1.01 | 1.14 | |||||
Fixed Assets Turnover | 17.57 | 11.53 | 11.59 | 12.95 | 15.11 | |||||
Receivables Turnover (Average Receivables) | 6.69 | 7.02 | 6.87 | 7.36 | 7.95 | |||||
Inventory Turnover (Average Inventory) | 66.18 | 54.27 | 45.25 | 38.29 | 41.34 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.41 | 1.5 | 1.18 | 1.22 | 1.27 | |||||
Quick Ratio | 1.23 | 1.36 | 1.01 | 1.02 | 1.08 | |||||
Operating Cash Flow to Current Liabilities | 0.67 | 0.67 | 0.73 | 0.39 | 0.46 | |||||
Days Sales Outstanding (Average Receivables) | 54.74 | 51.97 | 53.14 | 49.59 | 46.02 | |||||
Days Outstanding Inventory (Average Inventory) | 5.53 | 6.73 | 8.07 | 9.53 | 8.85 | |||||
Average Days Payable Outstanding | 10.23 | 11.04 | 20.27 | 20.65 | 17.29 | |||||
Cash Conversion Cycle (Average Days) | 50.04 | 47.66 | 40.93 | 38.47 | 37.58 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 68.57 | 81.99 | 69.28 | 64.26 | 54.54 | |||||
Total Debt / Total Capital | 40.68 | 45.05 | 40.92 | 39.12 | 35.29 | |||||
LT Debt/Equity | 64.27 | 77.93 | 66.07 | 61.4 | 51.35 | |||||
Long-Term Debt / Total Capital | 38.13 | 42.82 | 39.03 | 37.38 | 33.22 | |||||
Total Liabilities / Total Assets | 51.98 | 56.82 | 53.94 | 51.15 | 48.23 | |||||
EBIT / Interest Expense | 8.22 | 13.54 | 11.89 | 6.77 | 6.18 | |||||
EBITDA / Interest Expense | 11.97 | 19.3 | 17.41 | 9.6 | 8.48 | |||||
(EBITDA - Capex) / Interest Expense | 10.68 | 17.46 | 15.62 | 8.84 | 7.88 | |||||
Total Debt / EBITDA | 2.72 | 2.84 | 2.91 | 2.57 | 2.15 | |||||
Net Debt / EBITDA | 2.56 | 2.73 | 2.75 | 2.43 | 2 | |||||
Total Debt / (EBITDA - Capex) | 3.05 | 3.14 | 3.24 | 2.8 | 2.32 | |||||
Net Debt / (EBITDA - Capex) | 2.87 | 3.01 | 3.07 | 2.64 | 2.16 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.71 | 5.67 | 2.63 | 8.05 | 14.28 | |||||
Gross Profit, 1 Yr. Growth % | 18.94 | 5.62 | 1.81 | 6.88 | 9.24 | |||||
EBITDA, 1 Yr. Growth % | 20 | 16.97 | -5.08 | 12.37 | 11.68 | |||||
EBITA, 1 Yr. Growth % | 19.25 | 17.4 | -6.02 | 12.7 | 12.54 | |||||
EBIT, 1 Yr. Growth % | 18.05 | 17.86 | -7.99 | 14.34 | 14.49 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 21.04 | 42.29 | -19.82 | 4.89 | 9.15 | |||||
Net Income, 1 Yr. Growth % | 21.04 | 42.29 | -19.82 | 4.89 | 9.15 | |||||
Normalized Net Income, 1 Yr. Growth % | 18.9 | 24.39 | -9.02 | 6.39 | 12.61 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % |